Bulk Drugs

The Department of Pharmaceuticals had launched the PLI scheme for promotion of domestic manufacturing of critical bulk drugs — Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs).

India may lose out on potential bulk drug boom for lack of policy sops

The government, in its Draft Pharmaceutical Policy – 2017, had proposed several incentives to encourage local industries to take up the manufacture of bulk drugs. This included giving preference to the formulations produced from indigenously produced APIs in government procurements and taking them out of price control for five years.

Govt working on recommendations to reduce bulk drug imports

The government had earlier said "it is examining the recommendations of the committee which has recommended establishment of mega parks for APIs with common facilities".

Govt working on policy to raise bulk drugs output

"We have moved a Cabinet note on the basis of Katoch committee recommendations and at present it is under discussion," fertiliser minister Ananth Kumar said on Wednesday.

Expecting turnover of Rs 250 cr in FY17: NutraPlus

Speaking to CNBC-TV18, Mukesh Naik, MD of NutraPlus told that Cadila, Wanbury, Sun Pharma and Alkem Labs are some of their major clients where the former three contribute 20 percent to the company‘s sales.